Abatacept vs Belatacept After Kidney Transplant: Rejection Rates

Key Takeaways
- Among adults converted after kidney transplantation at three French centers, first-year rejection was observed at similar rates with abatacept and belatacept.
- Viral complications did not differ significantly between the conversion groups.
- Kidney-function evolution did not differ significantly between the conversion groups.
- No graft loss was reported with either treatment.
Investigators retrospectively assessed 74 adults converted at three centers in France’s Auvergne region from January 2017 through June 2023; 21 received abatacept and 53 received belatacept. Abatacept was given at 125 mg subcutaneously each week, while belatacept was given at 5 or 6 mg/kg intravenously every two weeks for two months, then monthly. Conversion was primarily associated with calcineurin inhibitor (CNI) toxicity or a marginal graft, or with chronic antibody-mediated rejection; belatacept shortages and difficult venous access often influenced selection of abatacept. The primary endpoint was Banff-defined T-cell–mediated or antibody-mediated rejection during the first postconversion year, assessed through biopsies obtained for clinical indications rather than routinely. Tacrolimus was used in both groups, and background corticosteroids were more frequent with belatacept. Treatment assignment was not randomized.
First-year rejection occurred in 2 of 21 abatacept recipients (9.5%) and 5 of 53 belatacept recipients (9.4%; p > 0.999). Most rejection episodes were T-cell–mediated; the remaining episode, in a belatacept recipient, involved microvascular inflammation without donor-specific antibody (DSA). New DSA appeared in both groups, and some abatacept recipients had increases in preexisting DSA. The observed rejection comparison did not establish that the treatments were equivalent.
Viral complications occurred in 2 of 21 abatacept recipients (9.5%) and 8 of 53 belatacept recipients (15.1%; p > 0.999). A nonviral opportunistic infection was reported in the belatacept group. Estimated glomerular filtration rate (eGFR) increased over the first postconversion year in both groups, without a statistically significant difference in its evolution. No graft loss was reported in either group.
Retrospective, nonrandom treatment selection complicates attribution of differences between abatacept and belatacept. The small abatacept group and differences in concomitant corticosteroid and tacrolimus regimens further limit comparison. Because biopsies followed clinical indications, subclinical rejection may have gone undetected. Nonsignificant comparisons do not demonstrate equivalence or noninferiority. The authors identified shortages and difficult venous access as circumstances in which abatacept could be of interest, without establishing a preferred conversion strategy.
The authors described abatacept as a potential maintenance option in selected circumstances, pending confirmation in larger studies. They called for further evaluation of the observed rejection and safety pattern after kidney transplant conversion.
Clinician Questions
How were donor-specific antibodies measured after kidney transplant conversion to abatacept or belatacept?
Among adults undergoing kidney transplant maintenance conversion to abatacept or belatacept, anti–human leukocyte antigen antibodies were assessed at scheduled intervals during the first year or with graft dysfunction. DSA positivity required a mean fluorescence intensity of 1000; a significant rise was defined as more than 50% above the preconversion value.
Which infections occurred after conversion to abatacept or belatacept in kidney transplant recipients?
Among adult kidney transplant recipients converted to maintenance abatacept or belatacept, abatacept recipients experienced cytomegalovirus colitis and zoster reactivation. A belatacept recipient developed cryptosporidium-induced diarrhea, a nonviral opportunistic infection. These individual events do not establish a comparative difference in infectious risk.
This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.